Related Announcements

PAR-21-237 - NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform applicants of a correction to PAR-21-237 "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)". This notice has been corrected to show that the initial milestone driven planning phase (UG3) will last for one year, with possible transition to the clinical phase, as outlined in the FOA. Changes to the Funding Opportunity Announcement (FOA) are shown below.

Currently Reads:

Part 2. Full Text of Announcement

Section 1. Funding Opportunity Description

Funding period: The grant mechanism used to support this funding announcement is a cooperative agreement (UG3/UH3) mechanism with two phases. The initial milestone-driven planning phase (UG3) will last for up to 2 years, with possible transition to the clinical phase, as outlined below. Only UG3 projects that have met scientific milestones and feasibility requirements will be approved to transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application. The UG3 phase will permit both scientific and operational planning activities. The UH3 phase of the award will support the clinical trial of the drug, biologic or device.

The UG3 Phase may not exceed 1 years

The UH3 Phase may not exceed 4 years

The total length of the project may not exceed 5 years

Modified to Read:

Part 2. Full Text of Announcement

Section 1. Funding Opportunity Description

Funding period: The grant mechanism used to support this funding announcement is a cooperative agreement (UG3/UH3) mechanism with two phases. The initial milestone-driven planning phase (UG3) will last for up to one year, with possible transition to the clinical phase, as outlined below. Only UG3 projects that have met scientific milestones and feasibility requirements will be approved to transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application. The UG3 phase will permit both scientific and operational planning activities. The UH3 phase of the award will support the clinical trial of the drug, biologic or device.

The UG3 Phase may not exceed 1 years

The UH3 Phase may not exceed 4 years

The total length of the project may not exceed 5 years

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Jeremy Brown, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135 
Email: Jeremy.brown@nih.gov